Serdar Farhan is a Cardiology physician. OpenAlex indexes 145 publications with 1,933 citations (h-index 26); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Gustave L Levy Pl
New York, NY 100296504
Telephone
212-241-3419Provider last certified this registry record 27 Feb 2020.
Clinical trials
- STRATegy SUccesS in High-Risk PCI With Impella CP: Evaluation of Hemodynamic Protection in Complex PCI
Sponsor: Rayyan Hemetsberger
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
35 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Medtronic, Inc.Program year202529 payments
- Endologix LLCProgram year20253 payments
- Stryker CorporationProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
76.2%Statin19%Atorvastatin Calcium62%Rosuvastatin Calcium34%Simvastatin5%Part D<11 patientsBeta blocker14.2%Metoprolol Succinate44%Carvedilol31%Bisoprolol Fumarate9%Metoprolol Tartrate7%Atenolol5%Propranolol Hcl Er5%Part D<11 patients+ 12 more classes in this area
Metabolism & gastrointestinal
14.8%SGLT2 inhibitor8.7%Jardiance64%Farxiga36%Part D≥34 patientsProton pump inhibitor4.2%Omeprazole57%Pantoprazole Sodium44%Part D<11 patients+ 1 more class in this area
Blood & clotting
6.9%Factor Xa inhibitor3.8%Eliquis80%Xarelto20%Part D<11 patientsP2Y12 inhibitor3.1%Clopidogrel59%Brilinta41%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”